ID   CHST8_HUMAN             Reviewed;         424 AA.
AC   Q9H2A9; Q9H3N2;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 2.
DT   10-MAY-2017, entry version 113.
DE   RecName: Full=Carbohydrate sulfotransferase 8;
DE            EC=2.8.2.-;
DE   AltName: Full=GalNAc-4-O-sulfotransferase 1;
DE            Short=GalNAc-4-ST1;
DE            Short=GalNAc4ST-1;
DE   AltName: Full=N-acetylgalactosamine-4-O-sulfotransferase 1;
GN   Name=CHST8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=10988300; DOI=10.1074/jbc.M007821200;
RA   Xia G., Evers M.R., Kang H.-G., Schachner M., Baenziger J.U.;
RT   "Molecular cloning and expression of the pituitary glycoprotein
RT   hormone N-acetylgalactosamine-4-O-sulfotransferase.";
RL   J. Biol. Chem. 275:38402-38409(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, TISSUE SPECIFICITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11001942; DOI=10.1074/jbc.M007983200;
RA   Okuda T., Mita S., Yamauchi S., Fukuta M., Nakano H., Sawada T.,
RA   Habuchi O.;
RT   "Molecular cloning and characterization of GalNAc 4-sulfotransferase
RT   expressed in human pituitary gland.";
RL   J. Biol. Chem. 275:40605-40613(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11445554; DOI=10.1093/glycob/11.6.495;
RA   Hiraoka N., Misra A., Belot F., Hindsgaul O., Fukuda M.;
RT   "Molecular cloning and expression of two distinct human N-
RT   acetylgalactosamine 4-O-sulfotransferases that transfer sulfate to
RT   GalNAc beta 1->4GlcNAc beta 1->R in both N- and O-glycans.";
RL   Glycobiology 11:495-504(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INDUCTION.
RX   PubMed=15632154; DOI=10.1074/jbc.M412635200;
RA   Barret A., Forestier L., Deslys J.-P., Julien R., Gallet P.F.;
RT   "Glycosylation-related gene expression in prion diseases: PrPSc
RT   accumulation in scrapie infected GT1 cells depends on beta-1,4-linked
RT   GalNAc-4-SO4 hyposulfation.";
RL   J. Biol. Chem. 280:10516-10523(2005).
RN   [6]
RP   TISSUE SPECIFICITY, INVOLVEMENT IN PSS3, VARIANT PSS3 TRP-77, AND
RP   CHARACTERIZATION OF VARIANT PSS3 TRP-77.
RX   PubMed=22289416; DOI=10.1016/j.ygeno.2012.01.005;
RA   Cabral R.M., Kurban M., Wajid M., Shimomura Y., Petukhova L.,
RA   Christiano A.M.;
RT   "Whole-exome sequencing in a single proband reveals a mutation in the
RT   CHST8 gene in autosomal recessive peeling skin syndrome.";
RL   Genomics 99:202-208(2012).
RN   [7]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-247.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Catalyzes the transfer of sulfate to position 4 of non-
CC       reducing N-acetylgalactosamine (GalNAc) residues in both N-glycans
CC       and O-glycans. Required for biosynthesis of glycoprotein hormones
CC       lutropin and thyrotropin, by mediating sulfation of their
CC       carbohydrate structures. Only active against terminal
CC       GalNAcbeta1,GalNAcbeta. Not active toward chondroitin.
CC       {ECO:0000269|PubMed:10988300, ECO:0000269|PubMed:11445554}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=10 uM for carbonic anhydrase VI
CC         {ECO:0000269|PubMed:11001942};
CC       pH dependence:
CC         Optimum pH is 7.2. {ECO:0000269|PubMed:11001942};
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000250};
CC       Single-pass type II membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in pituitary gland. In
CC       brain, it is expressed in pituitary gland, cerebellum, medulla
CC       oblongata, pons, thalamus and spinal cord. Expressed in the
CC       epidermis. Expressed at lower level in lung, spleen, adrenal
CC       gland, placenta, prostate, testis, mammary gland and trachea.
CC       {ECO:0000269|PubMed:10988300, ECO:0000269|PubMed:11001942,
CC       ECO:0000269|PubMed:11445554, ECO:0000269|PubMed:22289416}.
CC   -!- INDUCTION: Down-regulated (17-fold) in prion-infected cells.
CC       {ECO:0000269|PubMed:15632154}.
CC   -!- DISEASE: Peeling skin syndrome 3 (PSS3) [MIM:616265]: A form of
CC       peeling skin syndrome, a genodermatosis characterized by
CC       generalized, continuous shedding of the outer layers of the
CC       epidermis. Two main PSS subtypes have been suggested. Patients
CC       with non-inflammatory PSS (type A) manifest white scaling, with
CC       painless and easy removal of the skin, irritation when in contact
CC       with water, dust and sand, and no history of erythema, pruritis or
CC       atopy. Inflammatory PSS (type B) is associated with generalized
CC       erythema, pruritus and atopy. It is an ichthyosiform erythroderma
CC       characterized by lifelong patchy peeling of the entire skin with
CC       onset at birth or shortly after. Several patients have been
CC       reported with high IgE levels. PSS3 is characterized by
CC       generalized white scaling occurring over the upper and lower
CC       extremities. Symptoms start during the second half of the first
CC       decade of life. {ECO:0000269|PubMed:22289416}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 2 family.
CC       {ECO:0000305}.
CC   -!- CAUTION: PubMed:10988300 reports the possible existence of a
CC       secreted isoform starting at Met-119. However, they do not provide
CC       any experimental evidence. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF300612; AAG39444.1; -; mRNA.
DR   EMBL; AB047801; BAB19806.1; -; mRNA.
DR   EMBL; AF305781; AAL09373.1; -; mRNA.
DR   EMBL; BC011380; AAH11380.1; -; mRNA.
DR   EMBL; BC014250; AAH14250.1; -; mRNA.
DR   EMBL; BC018723; AAH18723.1; -; mRNA.
DR   CCDS; CCDS12433.1; -.
DR   RefSeq; NP_001121367.1; NM_001127895.1.
DR   RefSeq; NP_001121368.1; NM_001127896.1.
DR   RefSeq; NP_071912.2; NM_022467.3.
DR   RefSeq; XP_011525524.1; XM_011527222.1.
DR   RefSeq; XP_011525526.1; XM_011527224.1.
DR   RefSeq; XP_016882632.1; XM_017027143.1.
DR   UniGene; Hs.165724; -.
DR   ProteinModelPortal; Q9H2A9; -.
DR   BioGrid; 122148; 33.
DR   STRING; 9606.ENSP00000262622; -.
DR   iPTMnet; Q9H2A9; -.
DR   PhosphoSitePlus; Q9H2A9; -.
DR   BioMuta; CHST8; -.
DR   DMDM; 61212124; -.
DR   EPD; Q9H2A9; -.
DR   PaxDb; Q9H2A9; -.
DR   PeptideAtlas; Q9H2A9; -.
DR   PRIDE; Q9H2A9; -.
DR   TopDownProteomics; Q9H2A9; -.
DR   DNASU; 64377; -.
DR   Ensembl; ENST00000262622; ENSP00000262622; ENSG00000124302.
DR   Ensembl; ENST00000434302; ENSP00000392604; ENSG00000124302.
DR   Ensembl; ENST00000438847; ENSP00000393879; ENSG00000124302.
DR   GeneID; 64377; -.
DR   KEGG; hsa:64377; -.
DR   UCSC; uc002nus.5; human.
DR   CTD; 64377; -.
DR   DisGeNET; 64377; -.
DR   GeneCards; CHST8; -.
DR   H-InvDB; HIX0137482; -.
DR   HGNC; HGNC:15993; CHST8.
DR   MalaCards; CHST8; -.
DR   MIM; 610190; gene.
DR   MIM; 616265; phenotype.
DR   neXtProt; NX_Q9H2A9; -.
DR   OpenTargets; ENSG00000124302; -.
DR   Orphanet; 263548; Peeling skin syndrome type A.
DR   PharmGKB; PA26508; -.
DR   eggNOG; KOG4651; Eukaryota.
DR   eggNOG; ENOG4111GJR; LUCA.
DR   GeneTree; ENSGT00760000119214; -.
DR   HOGENOM; HOG000231801; -.
DR   HOVERGEN; HBG050950; -.
DR   InParanoid; Q9H2A9; -.
DR   KO; K09672; -.
DR   OMA; STADIQH; -.
DR   OrthoDB; EOG091G0FZO; -.
DR   PhylomeDB; Q9H2A9; -.
DR   TreeFam; TF325581; -.
DR   Reactome; R-HSA-975578; Reactions specific to the complex N-glycan synthesis pathway.
DR   SABIO-RK; Q9H2A9; -.
DR   GenomeRNAi; 64377; -.
DR   PRO; PR:Q9H2A9; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000124302; -.
DR   CleanEx; HS_CHST8; -.
DR   ExpressionAtlas; Q9H2A9; baseline and differential.
DR   Genevisible; Q9H2A9; HS.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0001537; F:N-acetylgalactosamine 4-O-sulfotransferase activity; IDA:UniProtKB.
DR   GO; GO:0016051; P:carbohydrate biosynthetic process; IEA:InterPro.
DR   GO; GO:0007417; P:central nervous system development; NAS:UniProtKB.
DR   GO; GO:0042446; P:hormone biosynthetic process; IEP:UniProtKB.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006790; P:sulfur compound metabolic process; IDA:UniProtKB.
DR   InterPro; IPR018011; Carb_sulfotrans_8-10.
DR   InterPro; IPR005331; Sulfotransferase.
DR   PANTHER; PTHR12137; PTHR12137; 1.
DR   Pfam; PF03567; Sulfotransfer_2; 1.
PE   1: Evidence at protein level;
KW   Carbohydrate metabolism; Complete proteome; Disease mutation;
KW   Glycoprotein; Golgi apparatus; Membrane; Polymorphism;
KW   Reference proteome; Signal-anchor; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    424       Carbohydrate sulfotransferase 8.
FT                                /FTId=PRO_0000189653.
FT   TOPO_DOM      1     10       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     11     31       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     32    424       Lumenal. {ECO:0000255}.
FT   NP_BIND     198    204       PAPS. {ECO:0000250}.
FT   NP_BIND     258    266       PAPS. {ECO:0000250}.
FT   CARBOHYD    128    128       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    294    294       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    367    367       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    415    415       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT      77     77       R -> W (in PSS3; results in decreased
FT                                enzyme activity; the mutant protein shows
FT                                reduced glycosylation;
FT                                dbSNP:rs149660944).
FT                                {ECO:0000269|PubMed:22289416}.
FT                                /FTId=VAR_067723.
FT   VARIANT     247    247       R -> H (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036538.
FT   CONFLICT    326    326       I -> T (in Ref. 1; AAG39444).
FT                                {ECO:0000305}.
SQ   SEQUENCE   424 AA;  48834 MW;  D4CEF1E7287D6102 CRC64;
     MTLRPGTMRL ACMFSSILLF GAAGLLLFIS LQDPTELAPQ QVPGIKFNIR PRQPHHDLPP
     GGSQDGDLKE PTERVTRDLS SGAPRGRNLP APDQPQPPLQ RGTRLRLRQR RRRLLIKKMP
     AAATIPANSS DAPFIRPGPG TLDGRWVSLH RSQQERKRVM QEACAKYRAS SSRRAVTPRH
     VSRIFVEDRH RVLYCEVPKA GCSNWKRVLM VLAGLASSTA DIQHNTVHYG SALKRLDTFD
     RQGILHRLST YTKMLFVREP FERLVSAFRD KFEHPNSYYH PVFGKAILAR YRANASREAL
     RTGSGVRFPE FVQYLLDVHR PVGMDIHWDH VSRLCSPCLI DYDFVGKFES MEDDANFFLS
     LIRAPRNLTF PRFKDRHSQE ARTTARIAHQ YFAQLSALQR QRTYDFYYMD YLMFNYSKPF
     ADLY
//
